PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
2.46
Current Ratio 0.5–0.75x Drug Manufacturers - Specialty & Generic median of 3.67. Guy Spier would worry about potential short-term pinch.
1.49
Quick Ratio below 0.5x Drug Manufacturers - Specialty & Generic median of 3.04. Jim Chanos might see a liquidity gap if the firm cannot tap more credit swiftly.
0.79
Cash Ratio below 0.5x Drug Manufacturers - Specialty & Generic median of 1.78. Jim Chanos might suspect near-term shortfall risks if credit markets seize up.
324.53
Positive interest coverage while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch would investigate our earnings advantages in a distressed sector.
No Data
No Data available this quarter, please select a different quarter.